Loading…

Yuhan000100.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Pharmaceuticals: Major

One of Korea's oldest and largest pharmaceutical companies, known for lung-cancer drug lazertinib and consumer health products.

Momentum strong 77
Mkt cap
$4.11B
US dollars, full cap
Free float
69%
of shares outstanding
$/day
$15.1M
20-day average traded
Fwd P/E
40.4×
forward earnings
ROIC−WACC
-1.4 pp
WACC 5.5%
Hurdle
n/a
no reverse DCF
Next earnings
91 days
17 Feb 2027
Close · KRW₩80,100
1D-3.7%
1W+1.4%
1M-7.1%
3M-4.3%
6M-10.4%
YTD-28.4%
1Y-29.7%
ATR %4.2%
52w lowhigh37.7% off high

What Yuhan does

One of Korea's oldest and largest pharmaceutical companies, known for lung-cancer drug lazertinib and consumer health products.

Sells prescription drugs, many in-licensed from foreign makers and distributed in Korea, and earns milestone payments and royalties from Janssen on lazertinib, the lung-cancer drug it discovered and licensed out in 2018. Yuhan-Kimberly, a joint venture with Kimberly-Clark making tissue and hygiene products, adds income through its stake.

Products and services

  • Lazertinib (Leclaza/Lazcluze, lung cancer)
  • Branded generic pharmaceuticals
  • Consumer health (Yuhan-Kimberly JV)

Customers

  • Hospitals/pharmacies (Korea)
  • Janssen/J&J (oncology licensing partner)

Where it sits in the supply chain

  • Pharmaceuticals
  • Branded/generic drugs and consumer…
  • Global oncology licensing

What could go right

  • Lazertinib global sales royalties
  • Consumer-health JV stability

What could go wrong

  • Clinical-trial/regulatory risk
  • Domestic drug-pricing regulation

Moat: narrow (IP / patents, brand). Lazertinib is a globally licensed, approved lung-cancer drug, unusual for a Korean pharma.

Headquarters: Seoul, South Korea · Founded: 1926 · Employees: 2,153

Named competitors

Yuhan at a glance

Size Yuhan (000100.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $4.11B, the 88th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩80,100 on 18 Nov 2026.

Performance Over six months the shares fell 10.4%, against +0.8% for the median peer and -37.2% for the South Korea market (cap-weighted) — 6th lowest of 20 in its peer set.

Growth Revenue grew 8.4% over the last twelve months (peer median +3.0%); the operating margin is 5.9% (peer median 19.2%).

Valuation It trades at 40.4× forward earnings against a peer median of 18.5× (2nd most expensive of 15).

Capital Return on invested capital runs 1.4 points below its cost of capital (5.5% WACC).

Next results Next results expected around 17 Feb 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 103000100.KS 93
Six months, rebased to 100: Yuhan against the median of its 20 peers (local-currency closes).

Yuhan financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩2.32T₩2.19T₩2.07T₩1.86T₩1.78T
Revenue growth—+6%+11%+5%—
Gross profit₩814B₩728B₩706B₩596B₩544B
EBITDA₩216B₩174B₩118B₩101B₩79.0B
Net income₩232B₩194B₩70.7B₩136B₩95.1B
Free cash flow-₩10.9B-₩3.63B-₩62.5B-₩17.4B₩41.2B
Capital expenditure₩191B₩145B₩134B₩204B₩94.4B
Total debt₩338B₩343B₩305B₩230B₩97.7B

Quarterly statements and history in the cockpit →

Yuhan competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%0%+50%4536DFTX128940002294CAMXAJANTPHARM688336600332ROVITARSXENEIONSSLS000100.KS6-month return →1-month return →
Up and to the right = strong over both horizons. Yuhan is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%20×40×4536128940002294CAMX600566AJANTPHARM688336600332600329ROVIOGN6005213320000100.KSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Yuhan is the large dot.

Yuhan competitors and peer comparison

Head to head with its named competitors (000100.KS vs 128940.KS vs AZN.L vs JNJ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Yuhan 000100.KS$4.11B-10%+8%6%40.4×n/a
HanmiPharm 128940.KS$3.95B-2%+14%16%15.0×4.7%
AstraZeneca AZN.L$278B-2%+5%23%17.6×14.4%
Johnson & Johnson JNJ$656B+20%+8%26%24.2×3.7%
Daewoong Pharm 069620.KS$856M-33%+9%12%9.0×n/a
Chongkundang 185750.KS$609M-27%+6%4%11.4×-6.6%
JW Pharmaceutical 001060.KS$423M-26%+9%13%6.3×-15.4%
GC Biopharma 006280.KS$1.12B-10%-3%4%4.6×n/a
Boryung 003850.KS$554M-13%+6%6%11.3×-3.1%

How Yuhan compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Yuhan against its 20 peers (data as of 18 Nov 2026)
Measure000100.KSPeer medianRank in peer set
1-month return-7.1%+0.2%6th lowest of 21
6-month return-10.4%+0.8%6th lowest of 20
Distance from 52-week high-37.7%-26.4%7th lowest of 21
Revenue growth (TTM)+8.4%+3.0%8th highest of 19
Operating margin5.9%19.2%5th lowest of 18
Forward P/E40.4×18.5×2nd most expensive of 15
ROIC minus cost of capital-1.4 pp+6.9 pp3rd lowest of 18
EV / EBITDA25.3×16.1×3rd most expensive of 9
Net debt / EBITDA-0.5×-0.1×4th least indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Yuhan 000100.KSSouth Korea$4.11B-10%+8%6%40.4×n/an/a
Santen Pharmaceutical 4536.TJapan$4.14B+10%+2%16%16.7×-5.0%+3.2%
Definium Therapeutics DFTXUnited States$3.99B+40%n/an/an/an/an/a
HanmiPharm 128940.KSSouth Korea$3.95B-2%+14%16%15.0×4.7%+7.5%
Novast Laboratories 301569.SZChina$3.92Bn/a+3%27%n/a57.4%+3.1%
Shenzhen Salubris Pharmaceuticals 002294.SZChina$4.31B-24%+14%11%35.4×12.4%+9.7%
Camurus CAMX.STSweden$4.36B+36%+3%38%45.1×7.9%+46.5%
HUBEI JUMPCAN PHARMACEUTICAL 600566.SSChina$4.36B+12%-4%32%16.2×-9.9%+0.3%
Ajanta Pharma AJANTPHARM.NSIndia$4.38B+1%+25%25%31.7×23.8%+13.8%
Sunshine Guojian Pharmaceutical (Shanghai) 688336.SSChina$3.81B-38%+227%74%39.9×0.9%+45.1%
Guangzhou Baiyunshan Pharmaceutical 600332.SSChina$4.45B-13%+1%3%12.9×-0.7%+4.7%
Livzon Pharmaceutical 000513.SZChina$3.76B+4%-14%19%16.9×-9.6%+2.7%
Tianjin Pharmaceutical Da Ren Tang 600329.SSChina$3.75B-10%-13%20%28.5×16.2%-5.8%
Laboratorios Farmaceuticos Rovi ROVI.MCSpain$3.75B+12%+14%20%21.9×1.2%+12.1%
Tarsus Pharmaceuticals TARSUnited States$3.74B+17%+86%-10%n/a34.7%+159.5%
Xenon Pharmaceuticals XENEUnited States$3.71B-31%-100%n/an/an/an/a
Ionis Pharmaceuticals IONSUnited States$4.56B-64%-1%-59%n/an/an/a
SELLAS Life Sciences SLSUnited States$3.66B+100%n/an/an/an/an/a
Organon & OGNUnited States$3.66B+3%-3%20%4.0×-4.1%-1.0%
Zhejiang Huahai Pharmaceutical 600521.SSChina$3.61B0%+10%12%20.1×6.4%+5.9%
China Resources Pharmaceutical 3320.HKHong Kong$3.60B-7%+8%4%5.8×-4.9%+7.8%

Questions

Who are Yuhan's main competitors?
Named competitors: HanmiPharm (128940.KS), AstraZeneca (AZN.L), Johnson & Johnson (JNJ), Daewoong Pharmaceutical (069620.KS), Chong Kun Dang (185750.KS), Dong-A ST (private or unlisted). The cockpit's measured peer set (industry) also includes Santen Pharmaceutical (4536.T), Definium Therapeutics (DFTX), HanmiPharm (128940.KS), Novast Laboratories (301569.SZ), Shenzhen Salubris Pharmaceuticals (002294.SZ), Camurus (CAMX.ST).
Is Yuhan expensive compared with its peers?
On forward p/e it trades at 40.4× against a peer median of 18.5×, 2nd most expensive of 15 in its peer set.
How has Yuhan stock performed?
Over six months to 18 Nov 2026 the shares returned -10.4% against +0.8% for the median peer; over one year -29.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.